Gestational Trophoblastic Neoplasia

Obstetrics and Gynecology Clinics of North America

Volumn 39, Issue 2, 2012, Pages 195-212

  Osborne, R ^a   Dodge, J ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Choriocarcinoma; Gestational; Neoplasm; Trophoblastic disease

Indexed keywords

BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PLATINUM; VINCRISTINE;

ALOPECIA; BONE MARROW DEPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CURETTAGE; CYTOTROPHOBLAST; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MOLECULAR PATHOLOGY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYNCYTIOTROPHOBLAST; TREATMENT FAILURE; TROPHOBLASTIC TUMOR; VISCERAL METASTASIS;

ANTIMETABOLITES, ANTINEOPLASTIC; CHORIOCARCINOMA; CHORIONIC GONADOTROPIN; DACTINOMYCIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; HYDATIDIFORM MOLE; METHOTREXATE; NEOPLASM STAGING; PREGNANCY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84861505298     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2012.03.002     Document Type: Review

References (84)

1. Li M., Hertz D. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956, 93:361-366.
2. Yarris J., Hunter A., Roy Hertz M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. Gynecol Oncol 2003, 89:193-198.
3. Zubrod C. Historic milestones in curative chemotherapy. Semin Oncol 1979, 6(4):490-505.
4. Willis L. Treatment of pernicious anaemia of pregnancy with folinic acid. Indian J Med Res 1930, 17:727-730.
5. Skibisz M., Tong S. Of leaves and butterflies: how methotrexate came to be the savior of women. Obstet Gynecol 2011, 118(5):1169-1173.
6. Shih I.-M., Kurman R. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gyncol Pathol 2001, 20(1):31-47.
7. Oldt R., Kurman R., Shih I.-M. Molecular genetic analysis of placental site trophoblastic tumors and epithelial trophoblastic tumors confirms their trophoblastic origin. Am J Pathol 2002, 161:1033-1037.
8. Messaed C, Wafaa W, Slim R, et al. NLRP7 in the spectrum of reproductive wastage [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
9. Betel C., Atri M., Osborne R., et al. Sonographic diagnosis of gestational trophoblastic disease and comparison to retained products of conception. J Ultrasound Med 2006, 25(8):985-993.
10. Sarmadi S., Izadi-Mood N., Abbasi A., et al. P57KIP2 immunohistochemical expression: a useful diagnostic tool in discrimination between complete hydatidiform mole and its mimics. Arch Gynecol Obstet 2011, 283(4):743-748.
11. Castrillon D., Sun D., Weremowicz S., et al. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol 2001, 25(10):1225-1230.
12. Fang F, Wan X, Xiang Y. The value of p57KIP2 and PHLDA2 immunohistochemistry and flow cytometry in the differential diagnosis of placental hydropic diseases [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
13. Chaing S., Faziollahi L., Nguyen A., et al. Diagnosis of hydatidiform moles by polymorphic deletion probe fluorescence in situ hybridization. J Mol Diagn 2011, 13(4):406-415.
14. Ronnett B., DeScipio C., Murphy K. Hydatidiform moles: ancillary techniques to refine diagnosis. Int J Gynecol Pathol 2011, 30(2):101-116.
15. Cole L. Human chorionic gonadotropin tests. Expert Rev Mol Diagn 2009, (7):721-747.
16. Cole L., Dutoit S., Higgins T. Total hCG tests. Clin Chem Acta 2011, 412(23-24):2216-2222.
17. Cole L. Human chorionic gonadotropin and associated molecules. Expert Rev Mol Diagn 2009, 9(1):51-73.
18. Cole L., Khanlian S. Hyperglycosylated hCG: a variant with separate biological functions to regular hCG. Mol Cell Endocrinol 2007, 2:260-262. 228-36.
19. Cole L., Shahabi S., Butler S., et al. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem 2001, 47(2):308-315.
20. Cole L., Kardana A. Discordant results in human chorionic gonadotropin assays. Clin Chem 1992, 38(2):263-270.
21. Hwang D., Hancock B. Management of persistent, unexplained, low-level human chorionic gonadotropin elevation: a report of 5 cases. J Reprod Med 2004, 49(7):559-562.
22. Cole L., Khanian S. Inappropriate management of women with persistent low hCG results. J Reprod Med 2004, 49(6):423-432.
23. White S., Harvey R., Mitchell H., et al. Characterization of transient benign hCG elevations in women following chemotherapy for GTT. J Obstet Gynaecol 2011, 31(2):169-172.
24. Knight A., Bingemann T., Cole L., et al. Frequent false positive beta human chorionic gonadotropin tests in immunoglobulin A deficiency. Clin Exp Immunol 2005, 14(2):333-337.
25. Cole L. Case report: phantom hCG and phantom choriocarcinoma. Gynecol Oncol 1998, 71:325-329.
26. Snyder J., Haymond S., Parvin C., et al. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin Chem 2005, 51(10):1830-1835.
27. Papapetrou P., Anagnostopoulos N. A gonadotropin and alpha-subunit suppression test for the assessment of the ectopic production of human chorionic gonadotropin and its subunits after the menopause. J Clin Endocrinol Metab 1985, 60(6):1187-1195.
28. Boafo-Yirenki A., Everard J., Tidy J., et al. A conservative approach in persistent low-level elevation of serum beta-human chorionic gonadotropin following chemotherapy for gestational trophoblastic neoplasia. J Reprod Med 2009, 54(5):288-290.
29. Agarwal R, Harding V, Alifrangis C, et al. Uterine artery pulsatility index (UAPI) is a predictor of methotrexate resistance in low-risk GTN (LR-GTN) independent of the FIGO score: a new standard of care? [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
30. Price J, Lo C, Abdi S, et al. Is there a role for CT thorax scanning when assessing gestational trophoblastic neoplasia? [abstract]. Presented at the XVII World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
31. Tidy J., Gillespie A., Bright N., et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000, 78:309-312.
32. Hammond C., Borchert L., Tyrey I., et al. Treatment of metastatic disease: good and poor prognosis. Am J Obstet Gynecol 1973, 115:451-457.
33. Hassadia A, Kew F, Tidy J, et al. Ectopic gestational trophoblastic disease: have we learned from previous experience [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
34. McGrath S., Short D., Harvey R., et al. The management and outcome of women with post-hydatidiform mole "low-risk" gestational trophoblastic neoplasia, but hCG levels in excess of 100,000 IU/L. Br J Cancer 2010, (102):810-814.
35. Osborne R., Filiaci V., Schink J., et al. Phase III trial of weekly methotrexate and pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011, 29(7):825-831.
36. Bagshawe K., Dent E., Newlands E., et al. The role of low-dose methotrexate and folinic acid on gestational trophoblastic tumours. Br J Obstet Gynaecol 1989, 96:795-802.
37. Hoestra A., Lurain J., Rademaker A., et al. Gestational trophoblastic neoplasia: treatment outcomes. Obstet Gynecol 2008, 112(2 Pt 1):251-258.
38. Gilani M., Yarandi F., Eftekhar Z., et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gyneacol 2005, 45(2):161-164.
39. Gleeson N., Finan M., Fiorica J., et al. Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 1993, 14(6):461-465.
40. 2) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2010, 117(3):477-480.
41. Mousavi A., Cheraghi F., Yarandi F., et al. Comparison of pulsed dactinomycin versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease. Int J Gynaecol Obstet 2012, 116(1):39-42.
42. Osborne R. Intermediate risk disease: have we made a mistake? [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
43. Wong L., Ngan H., Cheng K., et al. Methotrexate infusion for low-risk gestational trophoblastic neoplasia. Am J Obstet Gynecol 2000, 183(6):1579-1582.
44. Elit L., Covens A., Osborne R., et al. High-dose methotrexate for gestational trophoblastic disease. Gynecol Oncol 1994, 54(3):282-287.
45. Hitchins R., Holden L., Newlands E., et al. Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. Eur J Clin Oncol 1988, 24(6):1041-1046.
46. Eiriksson L., Wells T., Steed H., et al. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012, 124(3):553-557.
47. Limpongsanurak S. Prophylactic dactinomycin for high-risk hydatidiform mole. J Reprod Med 2001, 46(2):110-116.
48. Uberti E., Diestel M., Guimaraes F., et al. Single-dose dactinomycin: efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. Gynecol Oncol 2006, 102(2):325-332.
49. Goldstein D., Berkowitz R. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol 1995, 22:157-160.
50. Roberts J., Lurain J. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996, 174(6):1917-1923.
51. Osborne R. What is the best regimen for low-risk gestational trophoblastic neoplasia?. A review. J Reprod Med 2004, 49(8):602-616.
52. Alazzam M., Tidy J., Hancock B., et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009, 21(1). CD007102.
53. Soper J., Mutch D., Schink J., et al. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol 2004, 93(3):575-585.
54. Goldstein D., Garner E., Feltmate C., et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004, 95(3):421-422.
55. Massad L., Abu-Rustum N., Lee S., et al. Poor compliance with post-molar surveillance and treatment protocols by indigent women. Obstet Gynecol 2000, 96:940-944.
56. Kerkmeijer L., Wielsma S., Massuager L., et al. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecol Oncol 2007, 106(1):142-146.
57. Rotmensch J., Rosenshein N., Block B. Comparison of human chorionic gonadotropin regression in molar pregnancies and post-molar nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 1988, 29(1):82-86.
58. Shigematsu T., Hirakawa T., Yahata H., et al. Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol Oncol 1998, 71(3):376-380.
59. Kerkmeijer L., Thomas C., Harvey R., et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Brit J Cancer 2009, (100):979-984.
60. Dobson L., Lorigan P., Coleman R., et al. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Brit J Cancer 2000, 82(9):1547-1552.
61. Coleman R, Tidy J, Hancock B. Single agent dactinomycin as second line low risk treatment for gestational trophoblastic neoplasia: a decade of experience at the Sheffield Centre for Trophoblastic Disease, United Kingdom [abstract] Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
62. Newlands E., Bower M., Holden C., et al. Management of resistant gestational trophoblastic tumours. J Reprod Med 1998, 43(2):111-118.
63. Osborne R., Covens A., Gerulath A., et al. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med 2005, 54(3):320-327.
64. Bower M., Rustin G., Newlands E. Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur J Cancer 1998, 34(3):1204-1207.
65. Ngan H., Chan F., Au V., et al. Clinical outcome of micrometastasis in the lung in stage 1A persistent gestational trophoblastic disease. Gynecol Oncol 1998, 70:192-194.
66. Darby S., Jolley I., Pennington S., et al. Does chest CT matter in the staging of GTN?. Gynecol Oncol 2009, 112(1):155-160.
67. Athanassiou A., Begent R., Newlands E., et al. Central nervous system metastases of choriocarcinoma: 23 years experience at Charing Cross Hospital. Cancer 1983, 52:1728-1735.
68. Newlands E., Holden L., Seckl M., et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumours. J Reprod Med 2002, 47(6):465-471.
69. Yang J., Xiang Y., Yang X., et al. Emergency craniotomy in patients with intracranial metastatic gestational trophoblastic tumor. Int J Gynaecol Oncol 2005, 89(1):35-38.
70. Neubauer N, Latif N, Kalakota K, et al. Brain metastases in gestational trophoblastic neoplasia (GTN): an update [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
71. Doyle D., Einhorn L. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Oncol Biol Phys 2008, 70(5):1361-1364.
72. Azar J., Schneider B., Einhorn L. Is the blood-brain barrier relevant in metastatic germ cell tumor?. Int J Radiat Oncol Biol Phys 2007, 69(1):163-166.
73. Crawford R., Newlands E., Rustin G., et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 1997, 104(1):105-109.
74. Clark R., Nevadunsky N., Ghosh S., et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010, 55(5-6):194-198.
75. van Trommel N., Massuager L., Verheijen R., et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort study. Gynecol Oncol 2005, 99:6-13.
76. Pezeshki M., Hancock B., Silcocks P., et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004, 95(3):423-429.
77. Osborne R, Filiaci V, Schink D, et al. The role of second curettage in the primary management of persistent gestational trophoblastic neoplasia; a Gynecologic Oncology Group study.
78. Garner E., Meyerovitz M., Goldstein D., et al. Successful term pregnancy after selective arterial embolization of symptomatic arteriovenous malformation in the setting of gestational trophoblastic tumor. Gynecol Oncol 2003, 88:69-72.
79. Cockshott W., Hendrickse J. Persistent arteriovenous fistulae following chemotherapy of malignant trophoblastic disease. Radiology 1967, 88:329-333.
80. Stern W., Lopez F., Herzig N. Persistent angiographic abnormalities after cure of malignant trophoblastic disease. Radiology 1968, 91:1019-1021.
81. Method M., Hirschfield M., Averette H. Angiographic-guided embolization of metastatic invasive mole. Gynecol Oncol 1996, 61:442-445.
82. Massuager L. Developments in the management of gestational trophoblastic disease in the Netherlands. Are we on the right track? [abstract]. Presented at the XVI World Congress of the I.S.S.T.D. Budapest, Hungary, October 2011.
83. Cole L. HCG and hyperglycosylated hCG in the establishment of hemochorial placentation. J Reprod Immunol 2009, 82(2):112-118.
84. Cole L., Khanlian S., Kohorn E. Evolution of the human brain, chorionic gonadotropins and hemochorial implantation of the placenta: insights into the origin of pregnancy failures, preeclampsia and choriocarcinoma. J Reprod Med 2008, 53(8):549-557.